High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (≥65 years) myeloma patients : comparison with younger patients treated on the same protocol

Esa Jantunen,Taru Kuittinen,Karri Penttilä,Päivi Lehtonen,Eija Mahlamäki,Tapio Nousiainen

High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (≥65 years) myeloma patients : comparison with younger patients treated on the same protocol

2006

Esa Jantunen
Taru Kuittinen
Karri Penttilä
Päivi Lehtonen
Eija Mahlamäki
Tapio Nousiainen

High-dose melphalan (200 mg/m 2 ) supported by autologous stem cell transplantation is safe and effective in elderly (65 years) myeloma patients: comparison with younger patients treated on the same protocol

Keywords:

M.2
Immunology
Stem cell
Hematology
Melphalan
Medicine
Autologous stem-cell transplantation
Multiple myeloma
Nitrogen mustard
Internal medicine
Granulocyte colony-stimulating factor
Cyclophosphamide
Progenitor cell

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations